Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Total revenues	$ 74,205	$ 86,180	$ 1,615,797
Operating expenses:
Cost of revenue	845	2,765	146,319
Research and development	506,499	579,720	474,648
Selling, general and administrative	119,031	174,441	161,762
Restructuring, long-lived assets impairment and related charges	34,995	13,559	0
Total operating expenses	661,370	770,485	782,729
(Loss) income from operations	(587,165)	(684,305)	833,068
Other income (loss):
Change in fair value of equity investments	(5,528)	(21,888)	(111,140)
Interest income	71,809	86,990	28,092
Other (expense) income, net	(2,221)	(8,991)	4,260
Total other income (loss)	64,060	56,111	(78,788)
(Loss) income before benefit from (provision for) income taxes	(523,105)	(628,194)	754,280
Benefit from (provision for) income taxes	1,145	13,077	(238,443)
Net (loss) income	(521,960)	(615,117)	515,837
Net loss attributable to noncontrolling interest	0	(56)	0
Net (loss) income attributable to VirBio	$ (521,960)	$ (615,061)	$ 515,837
Net (loss) income per share attributable to VirBio, basic (in USD per share)	$ (3.83)	$ (4.59)	$ 3.89
Net (loss) income per share attributable to VirBio, diluted (in USD per share)	$ (3.83)	$ (4.59)	$ 3.83
Weighted-average shares outstanding, basic (in shares)	136,246,865	134,130,924	132,606,767
Weighted-average shares outstanding, diluted (in shares)	136,246,865	134,130,924	134,810,908
Collaboration revenue
Revenues:
Total revenues	$ 8,379	$ 37,266	$ 1,505,469
Contract revenue
Revenues:
Total revenues	55,333	2,228	52,714
License revenue from a related party
Revenues:
Total revenues	0	0	22,289
Grant revenue
Revenues:
Total revenues	$ 10,493	$ 46,686	$ 35,325